REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

1 Jul 2013 09:41

RNS Number : 2542I
Akers Biosciences, Inc.
01 July 2013
 



 

1 July 2013

 

 

Akers Biosciences, Inc.

 

("ABI" or the "Company")

 

Appointment of Non-Executive Directors

 

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

 

Mr Moran, aged 43, is an Irish national who has previously worked for Shell International in Shell Chemicals, Marketing, Finance and Shell International Trading. He then held a Trading role as a beneficial shareholder at Trafigura, a leading international commodities trading and logistics company based in Amsterdam and then a Trading role as a beneficial shareholder at Sono International based in London. Mr Moran is indirectly interested through Chubeworkx Guernsey Limited, in which he holds a 31.69 per cent. shareholding, 80 million common shares in the Company, which represents 28.70 per cent of the Company's shares and 24.30 per cent. of the Company's voting rights.

 

Mr Knox, aged 72, is a Philadelphia, Pennsylvania-based businessman who has owned, managed, and ultimately sold multiple profitable companies in the software, banking, and health insurance industries including Disc Systems, Inc., Crusader Bank, Gimco International, Kasser Industries and Fidelity Insurance Group. He also served as Chief Executive Officer for United HealthCare of Pennsylvania and served as Special Deputy Rehabilitator & Chief Executive Officer of Fidelity Mutual Life Insurance Co., Pennsylvania's 5th largest insurer. He currently holds 30 million common shares and 10 million preference shares, which represents 10.76 per cent of the Company's shares and 28.78 per cent. of the Company's voting rights.

 

Raymond F. Akers, Executive Chairman of ABI commented, "It gives me great pleasure to welcome Gavin and Thomas to our Board. They have both invested in the company in the past year and bring with them expertise and experience, which will help move the company forward in the future. My colleagues and I are very much looking forward to our working together."

Further information concerning Mr Moran

Gavin Edwin David Moran's directorships (current and within the previous 5 years) are as follows:

 

Current: None

 

Past: None

 

Further information concerning Mr Knox

 

Thomas James Knox, a Chartered Life Underwriter (CLU) and Chartered Financial Consultant (ChFC), has been involved in Philadelphia politics having held the position of Deputy Mayor for the Office of Management and Productivity. Mr Knox is the Chief Executive Officer of Knox Consulting Group, Knox Family Loan Company and INDECS Corp.

Thomas James Knox's directorships (current and within the previous 5 years) are as follows:

 

Current: Knox Consulting Group

Knox Family Loan Company

INDECS Corp

Historic Philadelphia, Inc.

Newman Wine and Spirit Company

ORB Automotive based in Shenzhen, China

 

Past: None

 

There is no further information required relating to Thomas J. Knox or Gavin E.D. Moran to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

 

 

 

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

End

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVFLBBXDFXBBK
Date   Source Headline
26th Nov 20099:28 amRNSHolding(s) in Company
25th Nov 20099:21 amRNSDirectorate Change
24th Nov 20097:00 amRNSHolding(s) in Company
4th Nov 20097:00 amRNSTrading Statement
30th Sep 20097:00 amRNSHalf Yearly Report
29th Sep 20097:00 amRNSABI Signs Malaria Test Distribution Agreement
13th Jul 20095:29 pmRNSResult of AGM
26th Jun 20099:19 amRNSAnnual Report & Accounts
25th Mar 20097:00 amRNSDirector/PDMR Shareholding
24th Mar 20097:00 amRNSFinal Results
19th Mar 20093:26 pmRNSHolding(s) in Company
11th Mar 20097:00 amRNSNotice of Preliminary Results
8th Jan 20091:48 pmRNSGrant of Warrants - Replacement
8th Jan 200912:00 pmRNSGrant of Warrants
8th Jan 20097:00 amRNSTrading Update
5th Jan 20097:00 amRNSTechnology Transfer & Supply Agreement
3rd Dec 20087:00 amRNSABI Sells Tax Losses in State of NJ, USA
20th Nov 20087:00 amRNSU.S. Over-the-Counter Distribution Agreement
27th Oct 20087:00 amRNSDirectorate Change
16th Sep 20083:17 pmRNSDirector/PDMR Shareholding
8th Sep 20087:30 amRNSNew Diagnostics in Diabetes
8th Sep 20087:00 amRNSInterim Results
4th Aug 20087:00 amRNSNotice of First Half Results
14th Jul 20087:00 amRNSABI Licenses Lithium System
26th Jun 20087:00 amRNSABI Signs New Distribution Ag
12th Jun 20083:50 pmRNSPlacing Update
11th Jun 20087:00 amRNSAdditional Listing
4th Jun 20089:00 amRNSAnnual Report and Accounts
4th Jun 20087:00 amRNSOption Agreement
9th Apr 20087:00 amRNSDirector/PDMR Shareholding
7th Apr 20087:01 amRNSFinal Results
3rd Apr 20087:00 amRNSDirectorate Change
14th Mar 200811:31 amRNSIssue of Equity
14th Jan 200810:17 amRNSIssue of Equity
7th Jan 20084:20 pmRNSResolution of Litigation
20th Dec 20077:01 amRNSDirector/PDMR Shareholding
18th Dec 200712:01 pmRNSChange of Adviser
28th Sep 200710:41 amRNSTotal Voting Rights
28th Sep 20077:00 amPRNDirectors' Shareholdings & Additional Listing
27th Sep 20077:00 amPRNHalf-yearly Report
18th Sep 20077:00 amPRNUnited States Military Contract
17th Sep 20077:00 amPRNUnited States Military Contract
12th Sep 20077:00 amPRNUK Sales Agency Agreement
7th Sep 200712:52 pmRNSIssue of Equity
21st Aug 20075:07 pmRNSChange of Nominated Adviser
17th Aug 20072:04 pmRNSAIM Rule 26
9th Aug 20077:00 amPRNDirectorate Change
8th Aug 20076:24 pmPRNAGM Statement
2nd Aug 20077:00 amPRNNotice of Results
31st Jul 20079:22 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.